S&P 500   4,593.00 (+1.20%)
DOW   35,237.55 (+1.90%)
QQQ   384.85 (+0.45%)
AAPL   166.28 (+2.74%)
MSFT   323.73 (+0.22%)
FB   315.65 (+2.87%)
GOOGL   2,851.48 (+0.40%)
AMZN   3,441.74 (+1.53%)
TSLA   992.16 (-2.25%)
NVDA   293.72 (-4.30%)
BABA   120.20 (+7.36%)
NIO   32.03 (-0.37%)
CGC   9.96 (-0.30%)
AMD   136.06 (-5.52%)
GE   96.72 (+4.26%)
MU   82.26 (+0.78%)
T   23.53 (+0.30%)
F   19.28 (+0.73%)
DIS   150.00 (+2.59%)
PFE   52.36 (-3.52%)
AMC   28.55 (-1.59%)
ACB   5.86 (+0.69%)
BA   205.92 (+3.74%)
S&P 500   4,593.00 (+1.20%)
DOW   35,237.55 (+1.90%)
QQQ   384.85 (+0.45%)
AAPL   166.28 (+2.74%)
MSFT   323.73 (+0.22%)
FB   315.65 (+2.87%)
GOOGL   2,851.48 (+0.40%)
AMZN   3,441.74 (+1.53%)
TSLA   992.16 (-2.25%)
NVDA   293.72 (-4.30%)
BABA   120.20 (+7.36%)
NIO   32.03 (-0.37%)
CGC   9.96 (-0.30%)
AMD   136.06 (-5.52%)
GE   96.72 (+4.26%)
MU   82.26 (+0.78%)
T   23.53 (+0.30%)
F   19.28 (+0.73%)
DIS   150.00 (+2.59%)
PFE   52.36 (-3.52%)
AMC   28.55 (-1.59%)
ACB   5.86 (+0.69%)
BA   205.92 (+3.74%)
S&P 500   4,593.00 (+1.20%)
DOW   35,237.55 (+1.90%)
QQQ   384.85 (+0.45%)
AAPL   166.28 (+2.74%)
MSFT   323.73 (+0.22%)
FB   315.65 (+2.87%)
GOOGL   2,851.48 (+0.40%)
AMZN   3,441.74 (+1.53%)
TSLA   992.16 (-2.25%)
NVDA   293.72 (-4.30%)
BABA   120.20 (+7.36%)
NIO   32.03 (-0.37%)
CGC   9.96 (-0.30%)
AMD   136.06 (-5.52%)
GE   96.72 (+4.26%)
MU   82.26 (+0.78%)
T   23.53 (+0.30%)
F   19.28 (+0.73%)
DIS   150.00 (+2.59%)
PFE   52.36 (-3.52%)
AMC   28.55 (-1.59%)
ACB   5.86 (+0.69%)
BA   205.92 (+3.74%)
S&P 500   4,593.00 (+1.20%)
DOW   35,237.55 (+1.90%)
QQQ   384.85 (+0.45%)
AAPL   166.28 (+2.74%)
MSFT   323.73 (+0.22%)
FB   315.65 (+2.87%)
GOOGL   2,851.48 (+0.40%)
AMZN   3,441.74 (+1.53%)
TSLA   992.16 (-2.25%)
NVDA   293.72 (-4.30%)
BABA   120.20 (+7.36%)
NIO   32.03 (-0.37%)
CGC   9.96 (-0.30%)
AMD   136.06 (-5.52%)
GE   96.72 (+4.26%)
MU   82.26 (+0.78%)
T   23.53 (+0.30%)
F   19.28 (+0.73%)
DIS   150.00 (+2.59%)
PFE   52.36 (-3.52%)
AMC   28.55 (-1.59%)
ACB   5.86 (+0.69%)
BA   205.92 (+3.74%)
NASDAQ:LIAN

LianBio Stock Forecast, Price & News

$8.57
-1.51 (-14.98%)
(As of 12/6/2021 12:27 PM ET)
Add
Compare
Today's Range
$8.57
$10.53
50-Day Range
N/A
52-Week Range
$8.73
$16.37
Volume
14,071 shs
Average Volume
338,664 shs
Market Capitalization
$902.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive LIAN News and Ratings via Email

Sign-up to receive the latest news and ratings for LianBio and its competitors with MarketBeat's FREE daily newsletter.


LianBio logo

About LianBio

LianBio is a cross-border biotechnology company dedicated to bringing medicines to patients principally in China and other major Asian markets. LianBio is based in SHANGHAI, China.

Headlines

LianBio's (NASDAQ:LIAN) Quiet Period To End on December 13th
December 6, 2021 |  americanbankingnews.com
LianBio (NASDAQ:LIAN) Shares Down 5.9%
December 1, 2021 |  americanbankingnews.com
LianBio (NASDAQ:LIAN) Hits New 12-Month Low at $12.43
November 30, 2021 |  americanbankingnews.com
LianBio (NASDAQ:LIAN) Shares Gap Down to $16.00
November 29, 2021 |  americanbankingnews.com
LianBio (NASDAQ:LIAN) Now Covered by Analysts at Bank of America
November 26, 2021 |  americanbankingnews.com
China-Focused Biotech LianBio Drops in U.S. Trading Debut
November 25, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LIAN
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$902.05 million
Optionable
Not Optionable

Company Calendar

Today
12/06/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.80 out of 5 stars

Medical Sector

845th out of 1,389 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












LianBio (NASDAQ:LIAN) Frequently Asked Questions

Is LianBio a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LianBio in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LianBio stock.
View analyst ratings for LianBio
or view top-rated stocks.

What price target have analysts set for LIAN?

4 brokerages have issued 12 month target prices for LianBio's stock. Their forecasts range from $18.58 to $27.00. On average, they anticipate LianBio's share price to reach $23.19 in the next year. This suggests a possible upside of 170.6% from the stock's current price.
View analysts' price targets for LianBio
or view top-rated stocks among Wall Street analysts.

When did LianBio IPO?

(LIAN) raised $325 million in an IPO on the week of November 1st 2021. The company issued 20,300,000 shares at a price of $16.00 per share. Goldman Sachs, Jefferies and BofA Securities acted as the underwriters for the IPO.

What is LianBio's stock symbol?

LianBio trades on the NASDAQ under the ticker symbol "LIAN."

When does the company's quiet period expire?

LianBio's quiet period expires on Monday, December 13th. LianBio had issued 20,312,500 shares in its initial public offering on November 1st. The total size of the offering was $325,000,000 based on an initial share price of $16.00. During the company's quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of LianBio?

Shares of LIAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LianBio's stock price today?

One share of LIAN stock can currently be purchased for approximately $8.57.

How much money does LianBio make?

LianBio has a market capitalization of $902.05 million.

What is LianBio's official website?

The official website for LianBio is www.lianbio.com.

How can I contact LianBio?

The company can be reached via phone at 609-486-2308 or via email at [email protected].


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.